18:17 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Clearside reports Phase II DME data for CLS-TA

Clearside Biomedical Inc. (NASDAQ:CLSD) reported that suprachoroidal CLS-TA plus Eylea aflibercept led to a smaller gain in visual acuity and a greater incidence of both elevated intraocular pressure and cataracts compared with Eylea alone in...
21:35 , May 31, 2018 |  BC Extra  |  Clinical News

Clearside falls on Phase II DME data

Clearside Biomedical Inc. (NASDAQ:CLSD) lost $4.68 (32%) to $9.86 on Thursday after reporting that suprachoroidal CLS-TA plus Eylea aflibercept led to a smaller gain in visual acuity and a greater incidence of both elevated intraocular...
17:03 , Mar 16, 2018 |  BC Week In Review  |  Financial News

Clearside, G1 price upsized follow-ons

Ophthalmology company Clearside Biomedical Inc. (NASDAQ:CLSD) and cancer company G1 Therapeutics Inc. (NASDAQ:GTHX) each priced bumped-up follow-ons on the back of positive data, raising a total of $199.8 million. Clearside raised $85 million on March 8...
17:18 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Clearside macular edema program headed for submission

Clearside Biomedical Inc. (NASDAQ:CLSD) reported that suprachoroidal CLS-TA met the primary endpoint in the Phase III PEACHTREE trial to treat macular edema associated with non-infectious uveitis. Clearside plans to submit an NDA to FDA in...
21:38 , Mar 8, 2018 |  BC Extra  |  Financial News

Clearside, G1 price upsized follow-ons

Ophthalmology company Clearside Biomedical Inc. (NASDAQ:CLSD) and cancer company G1 Therapeutics Inc. (NASDAQ:GTHX) each priced bumped-up follow-ons on the back of positive data, raising a total of $185.3 million. Clearside raised $85 million through the sale...
21:24 , Mar 5, 2018 |  BC Extra  |  Clinical News

Clearside macular edema program headed for submission

Clearside Biomedical Inc. (NASDAQ:CLSD) added $2.51 (32%) to $10.33 on Monday after reporting that suprachoroidal CLS-TA met the primary endpoint in the Phase III PEACHTREE trial to treat macular edema associated with non-infectious uveitis. Clearside...
20:46 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

FDA lifts clinical hold on Cellectis' CAR T candidate

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) said FDA lifted a clinical hold on Phase I testing of its chimeric antigen receptor (CAR) T cell candidate UCART123 to treat acute myelogenous leukemia (AML) and blastic plasmacytoid dendritic cell...
02:19 , Nov 7, 2017 |  BC Extra  |  Clinical News

FDA lifts clinical hold on Cellectis' CAR T candidate

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) said late Monday that FDA lifted a clinical hold on Phase I testing of its chimeric antigen receptor (CAR) T cell candidate UCART123 to treat acute myelogenous leukemia (AML) and blastic...
20:20 , Sep 8, 2017 |  BC Week In Review  |  Clinical News

FDA places hold on Phase I testing of Cellectis' CAR T UCART123

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) said a patient death prompted FDA to place a clinical hold on Phase I testing of its chimeric antigen receptor (CAR) T cell candidate UCART123. The company said it is discussing...
21:53 , Sep 5, 2017 |  BC Extra  |  Clinical News

Cellectis plummets after CAR T death

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) fell €5.67 (21%) to €21.17 in Europe and $6.52 (20%) to $25.66 on NASDAQ on Tuesday after a patient death prompted FDA to place a clinical hold on Phase I testing...